Publications by authors named "D Naber"
Article Synopsis
- The study aimed to evaluate the effects of Risperidone ISM on social functioning and health-related quality of life (HR-QoL) in patients with schizophrenia, using data from the PRISMA-3 study involving multiple phases and treatment groups.
- In the double-blind phase, patients receiving Risperidone ISM showed significant improvements in both social functioning (measured by the PSP scale) and HR-QoL (using the SWN-20 scale) compared to those on placebo, with benefits observed as early as Day 29.
- The findings suggest that Risperidone ISM offers a rapid and consistent enhancement in personal and social well-being, with the potential for improved therapeutic relationships and quicker patient
Background And Hypothesis: Meta-analyses have shown that the majority of patients with schizophrenia who have not improved after 2 weeks of treatment with an antipsychotic drug are unlikely to fully respond later. We hypothesized that switching to another antipsychotic with a different receptor binding profile is an effective strategy in such a situation.
Study Design: In total, 327 inpatients with an acute exacerbation of schizophrenia were randomized to double-blind treatment with either olanzapine (5-20 mg/day) or amisulpride (200-800 mg/day).
Objective: To evaluate long-term efficacy, safety and tolerability of Risperidone ISM® in patients with schizophrenia, a multicenter, open-label extension of the PRISMA-3 study was conducted.
Methods: Eligible placebo (unstable) and Risperidone ISM® (stabilized) rollover patients from a previous 12-week double-blind phase and de novo stable patients received once-monthly intramuscular injections of Risperidone ISM® 75 or 100 mg for 12 months. The long term-efficacy assessment included the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scales.
To evaluate the efficacy and safety of Risperidone ISM against placebo in patients with acute exacerbation of schizophrenia. A multicenter, randomized, double-blind, placebo-controlled study was conducted between June 2017 and December 2018 (NCT03160521). Eligible patients received once-monthly intramuscular injections of Risperidone ISM (75 or 100 mg) or placebo for 12 weeks.
View Article and Find Full Text PDF